» Articles » PMID: 15755756

Diphenyleneiodium (DPI) Reduces Oxalate Ion- and Calcium Oxalate Monohydrate and Brushite Crystal-induced Upregulation of MCP-1 in NRK 52E Cells

Overview
Date 2005 Mar 10
PMID 15755756
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Our earlier studies have demonstrated upregulation of monocyte chemoattractant protein-1 (MCP-1) in NRK52E rat renal epithelial cells by exposure to oxalate (Ox) ions and crystals of calcium oxalate monohydrate (COM) or the brushite (Br) form of calcium phosphate. The upregulation was mediated by reactive oxygen species (ROS). This study was performed to investigate whether NADPH oxidase is involved in ROS production.

Methods: Confluent cultures of NRK52E cells were exposed to Ox ions or COM and Br crystals. They were exposed for 1, 3, 6, 12, 24 and 48 h for isolation of MCP-1 mRNA and 24 h for enzyme-linked immunosorbent assay (ELISA) to determine the secretion of protein into the culture medium. We also investigated the effect of free radical scavenger, catalase, and the NADPH oxidase inhibitor diphenyleneiodium (DPI) chloride, on the Ox- and crystal-induced expression of MCP-1 mRNA and protein. The transcription of MCP-1 mRNA in the cells was determined using real-time polymerase chain reaction. Hydrogen peroxide and 8-isoprostane were measured to investigate the involvement of ROS.

Results: Exposure of NRK52E cells to Ox ions as well as the crystals resulted in increased expression of MCP-1 mRNA and production of the chemoattractant. Treatment with catalase reduced the Ox- and crystal-induced expression of both MCP-1 mRNA and protein. DPI reduced the crystal-induced gene expression and protein production but not Ox-induced gene expression and protein production.

Conclusions: Exposure to Ox ions, and COM and Br crystals stimulates a ROS-mediated increase in MCP-1 mRNA expression and protein production. Reduction in ROS production, lipid peroxidation, low-density lipoprotein release, and inducible MCP-1 gene and protein in the presence of DPI indicates an involvement of NADPH oxidase in the production of ROS.

Citing Articles

Cardiovascular and Cerebrovascular Morbidity in Patients with Urolithiasis: An Epidemiological Approach Based on Hospitalization Burden Data from 1997 to 2021.

Saenz-Medina J, Gomez Dos Santos V, Rodriguez-Monsalve M, Muriel-Garcia A, Duran-Poveda M, Gomez Del Val A J Clin Med. 2024; 13(12).

PMID: 38930093 PMC: 11204873. DOI: 10.3390/jcm13123564.


Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence.

Khan S, Canales B Asian J Urol. 2023; 10(3):246-257.

PMID: 37538166 PMC: 10394280. DOI: 10.1016/j.ajur.2023.01.008.


Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases.

Saenz-Medina J, Munoz M, Rodriguez C, Sanchez A, Contreras C, Carballido-Rodriguez J Int J Mol Sci. 2022; 23(2).

PMID: 35055099 PMC: 8778796. DOI: 10.3390/ijms23020912.


Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation.

Khan S, Canales B, Dominguez-Gutierrez P Nat Rev Nephrol. 2021; 17(6):417-433.

PMID: 33514941 DOI: 10.1038/s41581-020-00392-1.


LncRNA HOXA11-AS regulates calcium oxalate crystal-induced renal inflammation via miR-124-3p/MCP-1.

Li Y, Yan G, Zhang J, Chen W, Ding T, Yin Y J Cell Mol Med. 2019; 24(1):238-249.

PMID: 31680444 PMC: 6933336. DOI: 10.1111/jcmm.14706.